

# Global Anthrax Vaccine Market: Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2012 to 2016 and Forecast 2017 to 2023

<https://marketpublishers.com/r/G3C9EA9CBACEN.html>

Date: November 2017

Pages: 190

Price: US\$ 4,400.00 (Single User License)

ID: G3C9EA9CBACEN

## Abstracts

### Anthrax Vaccine Market

Anthrax is a severe infectious disease caused by bacillus anthracis. Signs and symptoms include vomiting, nausea, abdominal pain, headache, and loss of appetite, fever, severe bloody diarrhoea in the later stages of the disease, sore throat, and difficulty swallowing. Risk factors for anthrax include injection of illegal drugs, handling animal skins, and working in veterinary medicine, especially dealing with livestock. Global anthrax market is driven by growing threat of communicable diseases such as anthrax across the globe. Moreover cost-effectiveness of immunizations, new funding opportunities from government, donors, research foundations, advances in research and manufacturing technologies expected to drive market revenue growth of anthrax vaccine over a forecast period. In addition, availability of large target population in emerging markets driving the growth of the anthrax vaccines market. However, lack of awareness, the high cost of the vaccine in under developed economies, lack of availability and affordability, stringent regulations are the factors which are restraining the growth of the anthrax vaccine market.

Global anthrax vaccine market is segmented based on the type of vaccine, end user and geographical regions.

On the basis of type of vaccine, anthrax vaccine market is segmented as

Live Vaccines

Cell free PA Vaccines

On basis of end user, anthrax vaccine market is segmented as

Hospitals

Clinics

Vaccination Centres

Others

The growing efforts and of interest market players in expanding the product portfolio related to anthrax prevention are expected to to impel the market growth over the forecast period. Growing government funding in the United States to generate and store sufficient vaccines against anthrax through various programs, such as Joint Program Executive Office for Chemical and Biological Defense, Biomedical Advanced Research and Development Authority (BARDA), BioShield Legislation and is creating market opportunities for the market players. One of the U.S. FDA approved products against anthrax is BioThrax, manufactured by Emergent BioDefense Operations Lansing LLC, for active immunization against anthrax.

Geographically, Global anthrax vaccine is segmented into five key regions Viz. North America, Europe, Asia-Pacific, Latin America, and The Middle East & Africa. North America market expected to present better growth opportunities for market players owing to government initiatives to curb anthrax. The presence of various ongoing programs under the organizations such as BARDA, HHSCDC, NIAID, ASPR, and the FDA is one of the key contributing factors for the revenue generation in North America region. Asia Pacific is expected to witness a significant demand on account of surging investments in the R&D sector. The extensive vaccine manufacturing facilities across Japan coupled with the presence of sophisticated healthcare infrastructure in the country is contributing to its strong market position.

Some of the players in the anthrax vaccines market are Emergent BioSolutions (US), Elusys Therapeutics (US), Porton Biopharma Limited (UK), and Panacea Biotec (India) to name a few.

In 2015, Emergent BioDefense Operations Lansing LLC received U.S. FDA approval for

its BioThrax, a vaccine for Anthrax.

#### Report Outline:

The report provides granular level information about the market size, regional market share and forecast from 2017-2023

The report covers in-detail insights about the competitor's overview, key findings and their key strategies

The report outlines drivers, restraints, challenges, and trends that are currently faced by the industry

The report tracks recent innovations, key developments and startup's details that are working in the industry

The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario

## Contents

### **1. EXECUTIVE SUMMARY**

### **2. GLOBAL ANTHRAX MARKET INTRODUCTION**

#### 2.1. Global Anthrax Market – Taxonomy

#### 2.2. Global Anthrax Market –Definitions

##### 2.2.1. Type of vaccine

##### 2.2.2. End User

### **3. GLOBAL ANTHRAX MARKET DYNAMICS**

#### 3.1. Drivers

#### 3.2. Restraints

#### 3.3. Opportunities/Unmet Needs of the Market

#### 3.4. Trends

#### 3.5. Global Anthrax Market Dynamics – Factors Impact Analysis

#### 3.6. Global Anthrax Market – Regulations

##### 3.6.1. U.S

##### 3.6.2. Europe

##### 3.6.3. Japan

##### 3.6.4. China

#### 3.7. Global Anthrax Market – Product Innovations

### **4. GLOBAL ANTHRAX MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 – 2023**

#### 4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

#### 4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)

#### 4.3. Market Opportunity Analysis

### **5. GLOBAL ANTHRAX MARKET, BY TYPE OF VACCINE, 2012 - 2016 AND FORECAST, 2017 - 2023**

#### 5.1. Live Vaccine

##### 5.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

##### 5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

##### 5.1.3. Market Opportunity Analysis

## 5.2. Cell Free PA Vaccine

- 5.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
- 5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
- 5.2.3. Market Opportunity Analysis

## **6. GLOBAL ANTHRAX MARKET FORECAST, BY END USER, 2012 - 2016 AND FORECAST, 2017 - 2023**

### 6.1. Hospitals

- 6.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
- 6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
- 6.1.3. Market Opportunity Analysis

### 6.2. Clinics

- 6.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
- 6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
- 6.2.3. Market Opportunity Analysis

### 6.3. Vaccination Centres

- 6.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
- 6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
- 6.3.3. Market Opportunity Analysis

### 6.4. Others

- 6.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
- 6.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
- 6.4.3. Market Opportunity Analysis

## **7. GLOBAL ANTHRAX MARKET FORECAST, BY REGION, 2012 - 2016 AND FORECAST, 2017 - 2023**

### 7.1. North America

- 7.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
- 7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
- 7.1.3. Market Opportunity Analysis

### 7.2. Europe

- 7.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
- 7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
- 7.2.3. Market Opportunity Analysis

### 7.3. Asia-Pacific

- 7.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
- 7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

### 7.3.3. Market Opportunity Analysis

## 7.4. Latin America

7.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

7.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

7.4.3. Market Opportunity Analysis

## 7.5. Middle East and Africa

7.5.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

7.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

7.5.3. Market Opportunity Analysis

## 7.6. Global Anthrax Market - Opportunity Analysis Index, By Type of Vaccine, End User, and Region, 2017 – 2023

## **8. NORTH AMERICA ANTHRAX MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023**

8.1.1. Type of Vaccine Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

8.1.1.1. Live Vaccines

8.1.1.2. Cell free PA Vaccines

8.1.2. End User Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

8.1.2.1. Hospitals

8.1.2.2. Clinics

8.1.2.3. Vaccination Centres

8.1.2.4. Others

8.1.3. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)

8.1.3.1. U.S.

8.1.3.2. Canada

8.1.4. North America Anthrax Market - Opportunity Analysis Index, By Type of vaccine, End User and Country, 2017 – 2023

8.1.5. North America Anthrax Market Dynamics – Trends

## **9. EUROPE ANTHRAX MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023**

9.1.1. Type of Vaccine Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

9.1.1.1. Live Vaccines

9.1.1.2. Cell free PA Vaccines

9.1.2. End User Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

9.1.2.1. Hospitals

9.1.2.2. Clinics

9.1.2.3. Vaccination Centres

9.1.2.4. Others

9.1.3. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

9.1.3.1. Germany

9.1.3.2. UK

9.1.3.3. France

9.1.3.4. Spain

9.1.3.5. Italy

9.1.3.6. Russia

9.1.3.7. Poland

9.1.3.8. Rest of Europe

9.1.4. Europe Anthrax Market - Opportunity Analysis Index, By Type of Vaccine, End user and Country, 2017 – 2023

9.1.5. Europe Anthrax Market Dynamics – Trends

## **10. ASIA-PACIFIC ANTHRAX MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023**

10.1.1. Type of Vaccine Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

10.1.1.1. Live Vaccines

10.1.1.2. Cell free PA Vaccines

10.1.2. End User Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

10.1.2.1. Hospitals

10.1.2.2. Clinics

10.1.2.3. Vaccination Centres

10.1.2.4. Others

10.1.3. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

10.1.3.1. Japan

10.1.3.2. China

10.1.3.3. India

10.1.3.4. ASEAN

10.1.3.5. Australia & New Zealand

10.1.3.6. Rest of Asia-Pacific

10.1.4. Asia-Pacific Anthrax Market - Opportunity Analysis Index, By Type of vaccine, End-User and Country, 2017 – 2023

10.1.5. Europe Anthrax Market Dynamics – Trends

## **11. LATIN AMERICA ANTHRAX MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023**

11.1.1. Type of Vaccine Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

11.1.1.1. Live Vaccines

11.1.1.2. Cell free PA Vaccines

11.1.2. End User Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

11.1.2.1. Hospitals

11.1.2.2. Clinics

11.1.2.3. Vaccination Centres

11.1.2.4. Others

11.1.3. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

11.1.3.1. Brazil

11.1.3.2. Mexico

11.1.3.3. Argentina

11.1.3.4. Venezuela

11.1.3.5. Rest of Latin America

11.1.4. Latin America Anthrax Market - Opportunity Analysis Index, By Type of Vaccine, End User and Country, 2017 – 2023

11.1.5. Latin America Anthrax Market Dynamics – Trends

## **12. MIDDLE EAST AND AFRICA ANTHRAX MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023**

12.1.1. Type of Vaccine Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

12.1.1.1. Live Vaccines

12.1.1.2. Cell free PA Vaccines



12.1.2. End User Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

12.1.2.1. Hospitals

12.1.2.2. Clinics

12.1.2.3. Vaccination Centres

12.1.2.4. Others

12.1.3. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

12.1.3.1. Gulf Cooperation Council (GCC) Countries

12.1.3.2. Israel

12.1.3.3. South Africa

12.1.3.4. Rest of MEA

12.1.4. MEA Anthrax Market - Opportunity Analysis Index, By Type of Vaccine, End-User and Country, 2017 – 2023

12.1.5. MEA Anthrax Market Dynamics – Trends

## **13. COMPETITION LANDSCAPE**

13.1. Strategic Dashboard of Top Market Players

13.2. Company Profiles (Introduction, Financial Analysis, Product & Service Offerings, Key Developments, Strategies, and SWOT Analysis)

13.2.1. Emergent BioSolutions (U.S)

13.2.2. Elusys Therapeutics (U.S.)

13.2.3. Porton Biopharma Limited (UK)

13.2.4. Panacea Biotec (India)

## **14. RESEARCH METHODOLOGY**

## **15. KEY ASSUMPTIONS AND ACRONYMS**

## I would like to order

Product name: Global Anthrax Vaccine Market: Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2012 to 2016 and Forecast 2017 to 2023

Product link: <https://marketpublishers.com/r/G3C9EA9CBACEN.html>

Price: US\$ 4,400.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G3C9EA9CBACEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

